Epigeneres Biotech Pvt Ltd.

Liquid Biopsy Emerges as Top-Choice for Blood Cancer Diagnostics, Reporting Sales Growth at 9% CAGR: Fact.MR The recent market research study conducted by Fact.MR offers blood cancer diagnostics market demand outlook in term of key segments, including test type and end-user. The survey also reveals upcoming trends, and opportunities to capitalize on in the blood cancer diagnostics market Fact.MR – A Market Research and Competitive Intelligence Provider: The global blood cancer diagnostics market is expected to grow by 6% CAGR during the forecast period of 2021 to 2031. Rising prevalence of leukemia and awareness regarding the importance of early diagnosis have increased the demand for blood cancer diagnostics. According to the Leukemia & Lymphoma Society, every 9 minutes one person succumbs to blood cancer in the U.S. Approximately 158 people die every day due to late diagnosis or inefficient treatment of leukemia in the U.S. Hence, leading healthcare companies are focusing on investing in research and development (R&D) initiatives to ascertain prompt and accurate diagnosis. Coupled with this, favorable reimbursement policies and expanding healthcare infrastructure in emerging economies are supporting the blood cancer diagnostics market growth. For instance, the Government in India launched ‘Health Minister’s Cancer Patient Fund’ with ‘Rashtriya Arogya Nidhi’. Such initiatives are expected to create prospects for expansion through 2031. Request a report sample to gain comprehensive insights at Some of the leading companies are introducing advanced tests and diagnostics to cater the demand for improved diagnostics tests. For instance, in May 2021, Burning Rock Biotech Limited introduced its first blood-based pan-cancer study in China, based on a multi-omics approach. The study is dubbed as PRESCIENT (Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT). “Leading healthcare companies are investing extensively in R&D activities to develop advanced diagnostic tests that can detect tumors even before the symptoms appear. In order to improve the efficiency of tests and offer greater precision, market players are integrating advanced technologies such as real-time analysis and artificial intelligence. This is expected boost sales in the market in the coming years,” says a Fact.MR analyst. Key Takeaways from Blood Cancer Diagnostics Market Study Liquid biopsy is expected to dominate the market in terms of test type, exhibiting growth at 9% CAGR through 2031 CBC test type segment will register positive growth at 5% CAGR, surpassing US$ 77 Mn over the forecast period Hospital associated labs will account for high revenue share, expanding at 6% CAGR during the assessment period The U.S. is expected to dominate the North America blood cancer diagnostics market owing to the increasing sales of CTC tests for blood cancer diagnosis Germany and the U.K. will account for lion’s share in Europe blood cancer diagnostics market Asia Pacific is expected to register highest growth in the blood cancer diagnostics market, with India and China leading the market Key Drivers Increasing demand for cupping therapy (CT) test and genetic testing for blood cancer diagnostics will boost the market Rising prevalence of leukemia and awareness regarding necessity of early diagnosis will aid the blood cancer diagnostics market growth Favorable reimbursement policies implemented to improve healthcare infrastructure will create growth opportunities for blood cancer diagnostics market in emerging economies Ask Your Blood Cancer Diagnostics Market Related Questions & Get Customized Reports Competitive Landscape Leading blood cancer diagnostics manufacturers are focusing on product launches and new diagnostic methods to optimize their testing process. They also are adopting latest technologies and innovation, in compliance with standard policies, for faster approval. For instance, In February 2021, Grail Inc., leading healthcare company announced its collaboration with Quest Diagnostics, leading provider of diagnostic information services, to provide phlebotomy services to support Galleri, a Grail’s multi-cancer early detection blood test. In May 2021, Singapore based, Tzar labs, a molecular diagnostic company, in collaboration with Mumbai-based Epigeneres Biotechnology, announced an unprecedented breakthrough in early-detection and prognosis/diagnosis of cancer. In September 2021, NHS announced the launch of the world’s largest trial of a blood test which can detect more than 50 types of cancer before symptoms appear. Some of the key blood cancer diagnostics players profiled by Fact.MR are: Abbott Laboratories Roche Holding A.G. Thermo Fisher Scientific Inc. Laboratory Corporation of America Holdings Luminex Corporation Myriad Genetics Inc. Others More Valuable Insights on Blood Cancer Diagnostics Market Fact.MR, in its new report, offers comprehensive insights on the global blood cancer diagnostics market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in the blood cancer diagnostics market with detailed segmentation: By Test: CBC Tests CTC Tests Blood Protein Testing Liquid Biopsy Bone Marrow Biopsy By End User: Hospital Associated Labs Independent Diagnostic Laboratories Cancer Research Institutes Others By End User: Hospitals Ambulatory Surgery Centers Long-term Care Centers Others By Region: North America Latin America Europe Asia Pacific excluding Japan (APEJ) Middle East & Africa Key Questions Covered in the Blood Cancer Diagnostics Market Report The report offers insight into blood cancer diagnostics demand outlook for 2021-2031 The market survey also highlights projected sales growth for the blood cancer diagnostics market between 2021 and 2031 Blood cancer diagnostics market analysis identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry Blood cancer diagnostics market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, collaborations or partnerships, and others. Explore Fact.MR’s Coverage on the Healthcare Domain – CTC Diagnostics Market- Circulating tumor cells (CTCs) are a popular topic in cancer research, diagnosis, and treatment these days, as their ability to self-renew is one of the fundamental causes of carcinogenesis. Because of their accuracy and dependability in diagnosing cancer risks and monitoring various cancer treatments, CTC diagnostic tests are becoming increasingly used. In addition, an increasing number of end users, such as hospitals, diagnostic centers, research and academic institutes, and oncology labs, are seeking to engage with manufacturers in the CTC diagnostics field. The remarkable rise of the global circulating tumor cells market is being fueled by this. Lung Cancer Diagnostics Market- Increased expenditure for cancer treatment research is creating attractive chances for the early-stage lung cancer diagnostics market to flourish. The majority of lung cancer patients are diagnosed at an advanced stage where surgery or other therapy modalities will not be able to cure them. Lung cancer diagnosis is greatly influenced by the adoption of modern multimodal diagnostic methods. Over the projected period, increased development of lung cancer-specific biomarkers will drive demand for lung cancer diagnostics. Cancer Therapeutics Market- Stakeholders in the cancer therapeutics market are increasing research into novel delivery approaches in cancer care, such as integrating peptide vaccines, peptide-based pharmaceuticals, peptide-based therapies, and peptide-conjugated nanomaterials, to provide unique and more efficient cancer treatments. A new window of opportunity for peptide-based medications and peptide-based therapies in the cancer therapeutics industry is projected to open as a result of current research and clinical studies in tailored medicines for battling cancer. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making. MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs. You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Source: Fact.MR